schliessen

Filtern

 

Bibliotheken

NK cell-based immunotherapy for malignant diseases

Natural killer (NK) cells play critical roles in host immunity against cancer. In response, cancers develop mechanisms to escape NK cell attack or induce defective NK cells. Current NK cell-based cancer immunotherapy aims to overcome NK cell paralysis using several approaches. One approach uses expa... Full description

Journal Title: Cellular & molecular immunology May 2013, Vol.10(3), pp.230-52
Main Author: Cheng, Min
Other Authors: Chen, Yongyan , Xiao, Weihua , Sun, Rui , Tian, Zhigang
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: E-ISSN: 2042-0226 ; PMID: 23604045 Version:1 ; DOI: 10.1038/cmi.2013.10
Link: http://pubmed.gov/23604045
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: medline23604045
title: NK cell-based immunotherapy for malignant diseases
format: Article
creator:
  • Cheng, Min
  • Chen, Yongyan
  • Xiao, Weihua
  • Sun, Rui
  • Tian, Zhigang
subjects:
  • Immunotherapy
  • Killer Cells, Natural -- Immunology
  • Neoplasms -- Immunology
ispartof: Cellular & molecular immunology, May 2013, Vol.10(3), pp.230-52
description: Natural killer (NK) cells play critical roles in host immunity against cancer. In response, cancers develop mechanisms to escape NK cell attack or induce defective NK cells. Current NK cell-based cancer immunotherapy aims to overcome NK cell paralysis using several approaches. One approach uses expanded allogeneic NK cells, which are not inhibited by self histocompatibility antigens like autologous NK cells, for adoptive cellular immunotherapy. Another adoptive transfer approach uses stable allogeneic NK cell lines, which is more practical for quality control and large-scale production. A third approach is genetic modification of fresh NK cells or NK cell lines to highly express cytokines, Fc receptors and/or chimeric tumor-antigen receptors. Therapeutic NK cells can be derived from various sources, including peripheral or cord blood cells, stem cells or even induced pluripotent stem cells (iPSCs), and a variety of stimulators can be used for large-scale production in laboratories or good...
language: eng
source:
identifier: E-ISSN: 2042-0226 ; PMID: 23604045 Version:1 ; DOI: 10.1038/cmi.2013.10
fulltext: fulltext
issn:
  • 20420226
  • 2042-0226
url: Link


@attributes
ID923868212
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid23604045
sourceidmedline
recordidTN_medline23604045
sourceformatXML
sourcesystemPC
pqid1434036203
display
typearticle
titleNK cell-based immunotherapy for malignant diseases
creatorCheng, Min ; Chen, Yongyan ; Xiao, Weihua ; Sun, Rui ; Tian, Zhigang
ispartofCellular & molecular immunology, May 2013, Vol.10(3), pp.230-52
identifier
subjectImmunotherapy ; Killer Cells, Natural -- Immunology ; Neoplasms -- Immunology
descriptionNatural killer (NK) cells play critical roles in host immunity against cancer. In response, cancers develop mechanisms to escape NK cell attack or induce defective NK cells. Current NK cell-based cancer immunotherapy aims to overcome NK cell paralysis using several approaches. One approach uses expanded allogeneic NK cells, which are not inhibited by self histocompatibility antigens like autologous NK cells, for adoptive cellular immunotherapy. Another adoptive transfer approach uses stable allogeneic NK cell lines, which is more practical for quality control and large-scale production. A third approach is genetic modification of fresh NK cells or NK cell lines to highly express cytokines, Fc receptors and/or chimeric tumor-antigen receptors. Therapeutic NK cells can be derived from various sources, including peripheral or cord blood cells, stem cells or even induced pluripotent stem cells (iPSCs), and a variety of stimulators can be used for large-scale production in laboratories or good...
languageeng
source
version6
lds50peer_reviewed
links
openurl$$Topenurl_article
backlink$$Uhttp://pubmed.gov/23604045$$EView_this_record_in_MEDLINE/PubMed
openurlfulltext$$Topenurlfull_article
addlink$$Uhttp://exlibris-pub.s3.amazonaws.com/aboutMedline.html$$EView_the_MEDLINE/PubMed_Copyright_Statement
search
creatorcontrib
0Cheng, Min
1Chen, Yongyan
2Xiao, Weihua
3Sun, Rui
4Tian, Zhigang
titleNK cell-based immunotherapy for malignant diseases
descriptionNatural killer (NK) cells play critical roles in host immunity against cancer. In response, cancers develop mechanisms to escape NK cell attack or induce defective NK cells. Current NK cell-based cancer immunotherapy aims to overcome NK cell paralysis using several approaches. One approach uses expanded allogeneic NK cells, which are not inhibited by self histocompatibility antigens like autologous NK cells, for adoptive cellular immunotherapy. Another adoptive transfer approach uses stable allogeneic NK cell lines, which is more practical for quality control and large-scale production. A third approach is genetic modification of fresh NK cells or NK cell lines to highly express cytokines, Fc receptors and/or chimeric tumor-antigen receptors. Therapeutic NK cells can be derived from various sources, including peripheral or cord blood cells, stem cells or even induced pluripotent stem cells (iPSCs), and a variety of stimulators can be used for large-scale production in laboratories or good...
subject
0Immunotherapy
1Killer Cells, Natural -- Immunology
2Neoplasms -- Immunology
general
023604045
1English
2MEDLINE/PubMed (U.S. National Library of Medicine)
310.1038/cmi.2013.10
4MEDLINE/PubMed (NLM)
sourceidmedline
recordidmedline23604045
issn
020420226
12042-0226
rsrctypearticle
creationdate2013
addtitleCellular & molecular immunology
searchscope
0medline
1nlm_medline
2MEDLINE
scope
0medline
1nlm_medline
2MEDLINE
lsr41201305
citationpf 230 vol 10 issue 3
startdate20130501
enddate20130531
lsr30VSR-Enriched:[pqid, pages]
sort
titleNK cell-based immunotherapy for malignant diseases
authorCheng, Min ; Chen, Yongyan ; Xiao, Weihua ; Sun, Rui ; Tian, Zhigang
creationdate20130500
lso0120130500
facets
frbrgroupid3622977577179760798
frbrtype5
newrecords20190701
languageeng
creationdate2013
topic
0Immunotherapy
1Killer Cells, Natural–Immunology
2Neoplasms–Immunology
collectionMEDLINE/PubMed (NLM)
prefilterarticles
rsrctypearticles
creatorcontrib
0Cheng, Min
1Chen, Yongyan
2Xiao, Weihua
3Sun, Rui
4Tian, Zhigang
jtitleCellular &Amp; Molecular Immunology
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Cheng
1Chen
2Xiao
3Sun
4Tian
aufirst
0Min
1Yongyan
2Weihua
3Rui
4Zhigang
au
0Cheng, Min
1Chen, Yongyan
2Xiao, Weihua
3Sun, Rui
4Tian, Zhigang
atitleNK cell-based immunotherapy for malignant diseases
jtitleCellular & molecular immunology
risdate201305
volume10
issue3
spage230
pages230-252
issn1672-7681
eissn2042-0226
formatjournal
genrearticle
ristypeJOUR
abstractNatural killer (NK) cells play critical roles in host immunity against cancer. In response, cancers develop mechanisms to escape NK cell attack or induce defective NK cells. Current NK cell-based cancer immunotherapy aims to overcome NK cell paralysis using several approaches. One approach uses expanded allogeneic NK cells, which are not inhibited by self histocompatibility antigens like autologous NK cells, for adoptive cellular immunotherapy. Another adoptive transfer approach uses stable allogeneic NK cell lines, which is more practical for quality control and large-scale production. A third approach is genetic modification of fresh NK cells or NK cell lines to highly express cytokines, Fc receptors and/or chimeric tumor-antigen receptors. Therapeutic NK cells can be derived from various sources, including peripheral or cord blood cells, stem cells or even induced pluripotent stem cells (iPSCs), and a variety of stimulators can be used for large-scale production in laboratories or good...
doi10.1038/cmi.2013.10
pmid23604045
date2013-05